SCHEMBL6134093

SCHEMBL6134093

O=C(NCc1ccccn1)c1nc(-c2ccccc2)c(-c2ccc(=O)n(Cc3ccccc3)n2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
KMT2A Q03164 5/20 0.47
KDM4E B2RXH2 5/20 0.47
MEN1 O00255 4/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 4/20 0.45
HTT P42858 2/20 0.45
NAMPT P43490 1/20 0.45
ALDH1A1 P00352 5/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
POLB P06746 2/20 0.44
ADRB2 P07550 1/20 0.44
PKM P14618 1/20 0.44
TRPA1 O75762 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133417 0.90 KDM4E (0.49) CYP1A2CYP3A4CYP2C9KMT2AKDM4E
SCHEMBL6133820 0.88 KDM4E (0.52) CYP1A2CYP3A4CYP2C9KMT2AKDM4E
SCHEMBL6133701 0.88 KDM4E (0.46) CYP1A2CYP3A4CYP2C9KMT2AKDM4E
SCHEMBL6133540 0.87 KMT2A (0.51) CYP1A2CYP3A4CYP2C9KMT2AKDM4E
SCHEMBL6133509 0.86 TSHR (0.48) CYP1A2CYP3A4CYP2C9KMT2AKDM4E
SCHEMBL6133557 0.84 MEN1 (0.48) KMT2AKDM4EMEN1USP2HSD17B10
SCHEMBL6134249 0.84 TSHR (0.46) CYP1A2CYP3A4CYP2C9KMT2AKDM4E
SCHEMBL6134162 0.81 MEN1 (0.51) KMT2AKDM4EMEN1ALOX15ALDH1A1
SCHEMBL6133653 0.80 ALDH1A1 (0.54) KMT2AMEN1USP2L3MBTL1ALDH1A1
SCHEMBL6133541 0.78 LMNA (0.49) KMT2AKDM4EMEN1HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed
EP-1441732-A2 THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-04 EP disclosed
WO-2003039451-A2 THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR CYP1A2 114/4885CYP3A4 52/4885CYP2C9 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.